Statement: the primary trial and the secondary trial do not use the same route of administration for their interventions.
Primary_evidence: INTERVENTION 1:    Treatment (Vaccine Therapy+ex Vivo-expanded T Cells)   Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.   Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals.   HER-2/neu peptide vaccine: Given ID   leukapheresis: Undergo leukapheresis   ex vivo-expanded HER2-specific T cells: Given IV   cyclophosphamide: Given IV   sargramostim: Given ID   laboratory biomarker analysis: Correlative study
Secondary_evidence: INTERVENTION 1:    PET Guided Biopsy   No comparison group. All enrolled participants were expected to undergo PET guided biopsy.